How to Choose a DTC Measurement Platform for a Life Sciences Brand

DTC measurement vendors tend to look alike in a pitch deck. Each one will show a chart with exposed patients filling at a higher rate than unexposed ones, and each will say its data is privacy-safe. The differences that matter are underneath: whose patients are in the data, how the comparison group is built, and how long you wait for an answer. This article is part of the series that begins with the DTC pharma marketing guide.

What a DTC measurement platform does

A DTC measurement platform connects consumer ad exposures (from TV, CTV, digital, and social partners) to health outcomes in a privacy-safe way. In most US setups, exposure data and health data are tokenized separately, matched in a de-identified environment, and reported in aggregate. The outcome is usually prescriptions: new-to-brand starts, switches, and refills. Some vendors also measure diagnosis events or office visits.

Category examples include health data and analytics companies such as Veeva Crossix and IQVIA, plus measurement firms that partner with claims and pharmacy data providers. The right one for you depends on the criteria below, not on the brand name. For a wider view of the category, see pharma outcomes measurement platforms.

The seven criteria

1. Data source

Claims data shows what was billed and paid. Pharmacy data shows what was dispensed. EHR data shows what happened in the visit, including diagnoses and prescriptions written that may never be filled. Each misses things. The detail is in claims data vs. EHR data vs. lab data for campaign measurement.

2. Coverage of your patients

Ask what share of your brand's prescriptions the vendor's data captures, by channel. Specialty pharmacy, cash pay, manufacturer DTP programs, and certain payers are common gaps. A vendor with 60 percent coverage in retail pharmacy but little specialty coverage is a poor fit for a specialty brand.

3. Privacy model

Understand how de-identification works (expert determination or safe harbor under HIPAA), who holds the tokens, what minimum cell sizes apply, and whether any data leaves the environment. Also ask how the vendor handles state consumer health data laws for the exposure side.

4. Latency

How long from flight end to first read, and how often does the read refresh? Outcome data arrives later than media teams want. A vendor that delivers in six weeks rather than twelve gives you one more optimization cycle per year.

5. Methodology

This is where most of the difference sits. Ask how the unexposed group is built (matched on what variables, from what pool), whether randomized holdouts are supported, how prior treatment history is handled, and what the report calls "incremental." The distinction between attributed and incremental prescriptions matters a lot here.

6. Integrations

Check which of your TV, CTV, programmatic, social, and publisher partners already pass exposure data to the vendor, and how. Gaps in social and walled gardens are common. A platform that cannot see 30 percent of your spend gives you a partial answer.

7. Cost

Pricing models vary: per campaign, per brand per year, or by data volume. Ask about extra charges for custom analyses, additional partners, or longer lookback windows.

A scorecard you can use

The weights below are a suggestion, and the scores are illustrative for two hypothetical vendors.

In this example the vendors are close. Vendor B wins on methodology and latency, while Vendor A has better coverage and integrations. A close score is a signal to run a paid pilot on the same campaign before deciding.

Questions to put in the RFP

1. What share of our brand's prescriptions does your data capture, broken out by retail, mail, specialty, and cash?
2. How is the comparison group built, and can we run a randomized holdout?
3. What is the typical time from flight end to first read?
4. Which of our current media partners send exposure data to you today?
5. What minimum audience size or cell size applies to reporting?
6. What is included in the base fee, and what costs extra?

What usually goes wrong

Teams choose based on the demo dashboard, then discover in the first read that half the social spend was not measurable. Or they accept "lift" figures without asking how the unexposed group was built, and later find it was simply everyone not reached, who differ in many ways from those who were. Measurement should also connect to engagement data from your site and hub; see patient engagement and DTC analytics in one strategy.

Practical takeaway

Before talking to any vendor, pull your brand's prescription mix by dispensing channel and your media spend by partner. Those two lists are what you will check every vendor's coverage and integrations against, and they will eliminate weak fits in the first meeting.

Frequently asked questions

What does a DTC measurement platform measure?

It links consumer ad exposure to health outcomes, usually new-to-brand prescriptions, switches, refills, or diagnosis events, using de-identified claims, pharmacy, or EHR data. Better platforms compare exposed patients with a matched or randomized unexposed group to estimate incremental impact.

What is the most important criterion when choosing a DTC measurement platform?

Coverage of your actual patient population in the vendor's data source usually matters most. If the data misses the channels where your patients fill (specialty pharmacy, cash pay, certain payers), the results will be biased no matter how good the methodology is.

How long does DTC outcome measurement take?

It depends on the data source and vendor, but outcome reads usually lag media by several weeks to a few months because claims and pharmacy data take time to arrive and patients take time to act. Ask each vendor for their typical time from flight end to first read.

Should we use more than one DTC measurement vendor?

Some brands do, for example an Rx attribution vendor for campaign reads and a mix model for budget decisions. Using two attribution vendors for the same question tends to create argument rather than clarity. Define which decision each tool owns.

Sources

• HHS, Guidance Regarding Methods for De-identification of PHI
• Veeva, Crossix
• Media Rating Council, Standards and Guidelines

External guidance and platform documentation change. Links were current at publication; check them again before relying on them for a decision.

Editorial note. Analysis and frameworks are the author's own and do not represent Acxiom or any current or former employer, client, or named platform. Examples labeled hypothetical or illustrative are not results from real campaigns. Nothing here is legal, regulatory, or medical advice.